Improvement of myocardial blood flow by lipid-lowering therapy with pravastatin is modulated by apolipoprotein e genotype

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 67, Issue 7, 2007, Pages 723-734

  Ilveskoski, E ^a,b   Lehtimaki T ^a   Laaksonen, R ^a   Janatuinen, T ^c   Vesalainen, R ^c   Nuutila, P ^c   Laippala, P ^d   Karhunen, P J ^a,b   Knuuti, J ^c  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Atherosclerosis; Endothelium; Genetics; Pharmocogenetics; Positron emission tomography

Indexed keywords

ADENOSINE; APOLIPOPROTEIN E; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOUBLE BLIND PROCEDURE; GENOTYPE; HEART FUNCTION; HEART MUSCLE BLOOD FLOW; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERUM;

ADENOSINE; ADULT; ANALYSIS OF VARIANCE; APOLIPOPROTEINS E; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY CIRCULATION; DOUBLE-BLIND METHOD; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; POSITRON-EMISSION TOMOGRAPHY; PRAVASTATIN; TREATMENT OUTCOME;

EID: 35648930566     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510701297472     Document Type: Article

References (44)

1. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Natural history of aortic and coronary atherosclerotic lesions in youth. Findings from the PDAY Study. Arterioscler Thromb 1993;13:1291-98.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
3. DiCorleto PE, Gimbrone MA. Vascular endothelium. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven; 1996. pp 387-99.
4. Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol 1990;15:1032-42.
5. Laine H, Raitakari OT, Niinikoski H, Pitkänen OP, Iida H, Viikari J, et al. Early impairment of coronary flow reserve in young men with borderline hypertension. J Am Coll Cardiol 1998;32:147-53.
6. Pitkänen OP, Nuutila P, Raitakari OT, Rönnemaa T, Koskinen PJ, Iida H, et al. Coronary flow reserve is reduced in young men with IDDM. Diabetes 1998;47:248-54.
7. Pitkänen OP, Nuutila P, Raitakari OT, Porkka K, Iida H, Nuotio I, et al. Coronary flow reserve in young men with familial combined hyperlipidemia. Circulation 1999;99:1678-84.
8. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-30.
9. Utermann G, Hees M, Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature 1977;269:604-7.
10. Smith JD. Apolipoprotein E4: an allele associated with many diseases. Ann Med 2000;32:118-27.
11. Lehtimäki T, Moilanen T, Viikari J, Åkerblom HK, Ehnholm C, Rönnemaa T, et al. Apolipoprotein E phenotypes in Finnish youths: a cross-sectional and 6-year follow-up study. J Lipid Res 1990;31:487-95.
12. Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 1985;37:268-85.
13. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb VascBiol 1996;16:1250-5.
14. Ilveskoski E, Perola M, Lehtimäki T, Laippala P, Savolainen V, Pajarinen J, et al. Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: an autopsy study. Circulation 1999;100:608-13.
15. Judson R, Brain C, Dain B, Windemuth A, Ruano G, Reed C. New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals. Atherosclerosis 2004;177:345-51.
16. Rontu R, Ojala P, Hervonen A, Goebeler S, Karhunen PJ, Nikkilä M, et al. Apolipoprotein E genotype is related to plasma levels of C-reactive protein and lipids and to longevity in nonagenarians. Clin Endocrinol (Oxf) 2006;64:265-70.
17. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
18. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J Am Med Assoc 1998;279:1615-22.
19. Scandinavian Simvastatin Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
20. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherfor JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
21. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
22. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latifi R, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 1994;89:1530-8.
23. Baller D, Notohamiprodjo G, Gleichmann U, Holzinger J, Weise R, Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999;99:2871-5.
24. Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, Hansen PS, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 2000;101:1366-71.
25. Ballantyne CM, Herd JA, Stein EA, Ferlic LL, Dunn JK, Gotto AM Jr, et al. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol 2000;36:1572-8.
26. Janatuinen T, Laaksonen R, Vesalainen R, Raitakari O, Lehtimäki T, Nuutila P, et al. Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults. J Cardiovasc Pharmacol 2001;38:561-8.
27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
28. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-8.
29. Clark JC, Crouzel C, Meyer GJ, Strijckmans K. Current methodology for oxygen-15 production for clinical use. Int J Rad Appl Instrum 1987;38:597-600.
30. Crouzel C, Clark J, Brihaye C, et al. Radiochemistry automation for PET. In: Stöckling G, Pike V, editors. Radiopharmaceuticals for positron emission tomography. The Netherlands: Kluwer Academic Publishers; 1993. pp 45-90.
31. 15O and dynamic positron-emission tomography. Strategy for quantification in relation to the partial-volume effect. Circulation 1988;78:104-15.
32. Iida H, Takahashi A, Tamura Y, Ono Y, Lammertsma AA. Myocardial blood flow: comparison of oxygen-15-water bolus injection, slow infusion and oxygen-15-carbon dioxide slow inhalation. J Nucl Med 1995;36:78-85.
33. Iida H, Rhodes C, de Silva R, Araujo LI, Bloomfield PM, Lammertsma AA, et al. Use of the left ventricular time-activity curve as a noninvasive input function in dynamic oxygen-15-water positron emission tomography. J Nucl Med 1992;33:1669-77.
34. O'Malley JP, Illingworth DR. The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia. Metabolism 1990;39:150-4.
35. Ojala JP, Helve E, Ehnholm C, Aalto-Setälä K, Kontula KK, Tikkanen MJ. Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. J Intern Med 1991;230:397-405.
36. John S, Schlaich M, Langenfeld M, Weihprecht H, Schmidt G, Weidinger G, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998;98:211-16.
37. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 1998;97:1129-35.
38. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996;14:55-61.
39. Aviram M. Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants. Eur J Clin Chem Clin Biochem 1996;34:599-608.
40. Ridker PM. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 2004;148:S19-26.
41. Leipert B, Becker BF, Gerlach E. Different endothelial mechanisms involved in coronary responses to known vasodilators. Am J Physiol 1992;262:H1676-83.
42. Mayhan WG. Endothelium-dependent responses of cerebral arterioles to adenosine 5′-diphosphate. J Vasc Res 1992;29:353-8.
43. Buus NH, Bottcher M, Hermansen F, Sander M, Nielsen TT, Mulvany MJ. Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation 2001;104:2305-10.
44. Wilson RF, Wyche K, Christensen BV, Zimmer S, Laxson DD. Effects of adenosine on human coronary arterial circulation. Circulation 1990;82:1595-606.